GlassScriptPhysician profile
Lissa Rhodes
NPI 1467987099
$2,016.18
in general payments reported to CMS, 2019-2025
19 companies · $606 in 2025
The $606 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $144 · 2023: $551 · 2024: $597 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,582 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,581.55 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $544.73 | 2021-2025 | Xeomin |
| Janssen Biotech, INC. | $382.98 | 2023-2025 | Tremfya |
| Abbvie INC. | $181.67 | 2023-2025 | |
| Genzyme Corporation | $167.29 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $117.01 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $112.47 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $107.41 | 2023-2025 | Aklief, Nemluvio |
| Sun Pharmaceutical Industries INC. | $69.18 | 2021-2025 | |
| Ucb, INC. | $64.51 | 2024-2025 | Bimzelx |
| Organon LLC | $47.43 | 2025 | Vtama |
| Amgen INC. | $33.00 | 2025 | Otezla |
| Pfizer INC. | $31.93 | 2023-2024 | |
| Mayne Pharma Commercial LLC | $29.37 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $24.75 | 2022 | |
| Almirall LLC | $23.93 | 2025 | Seysara |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $20.25 | 2025 | Acthar |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.77 | 2024 | Jublia, Arazlo |
| Novartis Pharmaceuticals Corporation | $19.46 | 2025 | |
| Incyte Corporation | $19.04 | 2025 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lissa Rhodes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.